{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:33:26Z","timestamp":1744716806104,"version":"3.40.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,7,22]],"date-time":"2012-07-22T00:00:00Z","timestamp":1342915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s00296-012-2472-7","type":"journal-article","created":{"date-parts":[[2012,7,21]],"date-time":"2012-07-21T14:43:05Z","timestamp":1342881785000},"page":"913-919","source":"Crossref","is-referenced-by-count":8,"title":["The HLA-Cw*06 allele and \u22121149 G\/T polymorphism of extrapituitary promoter of PRL gene as a possible common genetic predisposing factors to psoriasis vulgaris and psoriatic arthritis in Czech population"],"prefix":"10.1007","volume":"33","author":[{"given":"Anna","family":"Cibulova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Zajacova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marketa","family":"Fojtikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Stolfa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Sedova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavlina","family":"Cejkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Lippert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Arenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Cerna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,22]]},"reference":[{"issue":"Suppl 2","key":"2472_CR1","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(Suppl 2):ii14\u2013ii17","journal-title":"Ann Rheum Dis"},{"key":"2472_CR2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s100670200097","volume":"21","author":"GM Alenius","year":"2002","unstructured":"Alenius GM, Jidell E, Nordmark L, Rantap\u00e4\u00e4 Dahlqvist S (2002) Disease manifestations and HLA antigens in psoriatic arthritis in northern Sweden. Clin Rheumatol 21:357\u2013362","journal-title":"Clin Rheumatol"},{"key":"2472_CR3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/PL00011173","volume":"19","author":"O Elkayam","year":"2000","unstructured":"Elkayam O, Ophir J, Yaron M, Caspi D (2000) Psoriatic arthritis: interrelationships between skin and joint manifestations related to onset, course and distribution. Clin Rheumatol 19:301\u2013305","journal-title":"Clin Rheumatol"},{"issue":"Suppl 2","key":"2472_CR4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1468-3083.2006.01774.x","volume":"20","author":"J Sibilia","year":"2006","unstructured":"Sibilia J (2006) Psoriasis: skin and joints, same fight? J Eur Acad Dermatol Venereol 20(Suppl 2):56\u201372","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2472_CR5","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/1529-0131(199905)42:5<1010::AID-ANR21>3.0.CO;2-H","volume":"42","author":"S Gonzalez","year":"1999","unstructured":"Gonzalez S, Martinez-Borra J, Torre-Alonso JC, Gonzalez-Roces S, Sanchez del R\u00edo J, Rodriguez P\u00e9rez A, Brautbar C, L\u00f3pez-Larrea C (1999) The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Arthritis Rheum 42:1010\u20131016","journal-title":"Arthritis Rheum"},{"key":"2472_CR6","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N","volume":"41","author":"DD Gladman","year":"1998","unstructured":"Gladman DD, Farewell VT, Wong K, Husted J (1998) Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 41:1103\u20131110","journal-title":"Arthritis Rheum"},{"key":"2472_CR7","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1046\/j.0022-202x.2001.01656.x","volume":"118","author":"JE Gudj\u00f3nsson","year":"2002","unstructured":"Gudj\u00f3nsson JE, K\u00e1rason A, Antonsd\u00f3ttir AA, R\u00fanarsd\u00f3ttir EH, Gulcher JR, Stef\u00e1nsson K, Valdimarsson H (2002) HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. J Invest Dermatol 118:362\u2013365","journal-title":"J Invest Dermatol"},{"key":"2472_CR8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0190-9622(85)70188-0","volume":"13","author":"T Henseler","year":"1985","unstructured":"Henseler T, Christophers E (1985) Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 13:450\u2013456","journal-title":"J Am Acad Dermatol"},{"key":"2472_CR9","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2133.1995.tb02753.x","volume":"133","author":"G Swanbeck","year":"1995","unstructured":"Swanbeck G, Inerot A, Martinsson T, Wahlstr\u00f6m J, Enerb\u00e4ck C, Enlund F, Yhr M (1995) Age at onset and different types of psoriasis. Br J Dermatol 133:768\u2013773","journal-title":"Br J Dermatol"},{"key":"2472_CR10","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1086\/503821","volume":"78","author":"RP Nair","year":"2006","unstructured":"Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NV, Jenisch S, Weichenthal M, Abecasis GR, Lim HW, Christophers E, Voorhees JJ, Elder JT (2006) Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 78:827\u2013851","journal-title":"Am J Hum Genet"},{"key":"2472_CR11","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/hmg\/6.5.813","volume":"6","author":"RC Trembath","year":"1997","unstructured":"Trembath RC, Clough RL, Rosbotham JL, Jones AB, Camp RD, Frodsham A, Browne J, Barber R, Terwilliger J, Lathrop GM, Barker JN (1997) Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 6:813\u2013820","journal-title":"Hum Mol Genet"},{"key":"2472_CR12","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.4049\/jimmunol.169.6.2818","volume":"169","author":"MP Martin","year":"2002","unstructured":"Martin MP, Nelson G, Lee JH, Pellett F, Gao X, Wade J, Wilson MJ, Trowsdale J, Gladman D, Carrington M (2002) Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 169:2818\u20132822","journal-title":"J Immunol"},{"key":"2472_CR13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.clindermatol.2007.08.010","volume":"25","author":"H Valdimarsson","year":"2007","unstructured":"Valdimarsson H (2007) The genetic basis of psoriasis. Clin Dermatol 25:563\u2013567","journal-title":"Clin Dermatol"},{"key":"2472_CR14","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1086\/302932","volume":"66","author":"RP Nair","year":"2000","unstructured":"Nair RP, Stuart P, Henseler T, Jenisch S, Chia NV, Westphal E, Schork NJ, Kim J, Lim HW, Christophers E, Voorhees JJ, Elder JT (2000) Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet 66:1833\u20131844","journal-title":"Am J Hum Genet"},{"key":"2472_CR15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1086\/345646","volume":"72","author":"A Karason","year":"2003","unstructured":"Karason A, Gudjonsson JE, Upmanyu R, Antonsdottir AA, Hauksson VB, Runasdottir EH, Jonsson HH, Gudbjartsson DF, Frigge ML, Kong A, Stefansson K, Valdimarsson H, Gulcher JR (2003) A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. Am J Hum Genet 72:125\u2013131","journal-title":"Am J Hum Genet"},{"key":"2472_CR16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2370.2004.00452.x","volume":"31","author":"Z Grubi\u0107","year":"2004","unstructured":"Grubi\u0107 Z, Peri\u0107 P, Ee\u00e8uk-Jelici\u0107 E, Zunec R, Stingl K, Curkovi\u0107 B, Kerhin-Brkljaci\u0107 V (2004) The MICA-A4 triplet repeats polymorphism in the transmembrane region confers additional risk for development of psoriatic arthritis in the Croatian population. Eur J Immunogenet 31:93\u201398","journal-title":"Eur J Immunogenet"},{"key":"2472_CR17","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/ard.2006.064972","volume":"66","author":"PY Ho","year":"2007","unstructured":"Ho PY, Barton A, Worthington J, Thomson W, Silman AJ, Bruce IN (2007) HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis. Ann Rheum Dis 66:807\u2013811","journal-title":"Ann Rheum Dis"},{"key":"2472_CR18","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00296-009-0847-1","volume":"29","author":"M Fojtikova","year":"2009","unstructured":"Fojtikova M, Stolfa J, Novota P, Cejkova P, Dostal C, Cerna M (2009) HLA-Cw*06 class I region rather than MICA is associated with psoriatic arthritis in Czech population. Rheumatol Int 29:1293\u20131299","journal-title":"Rheumatol Int"},{"key":"2472_CR19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1043-4666(02)00496-9","volume":"21","author":"KZ Matalka","year":"2003","unstructured":"Matalka KZ (2003) Prolactin enhances production of interferon-gamma, interleukin-12, and interleukin-10, but not of tumor necrosis factor-alpha, in a stimulus-specific manner. Cytokine 21:187\u2013194","journal-title":"Cytokine"},{"key":"2472_CR20","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1210\/en.2006-1639","volume":"148","author":"N Kanda","year":"2007","unstructured":"Kanda N, Watanabe S (2007) Prolactin enhances interferon-gamma-induced production of CXC ligand 9 (CXCL9), CXCL10, and CXCL11 in human keratinocytes. Endocrinology 148:2317\u20132325","journal-title":"Endocrinology"},{"key":"2472_CR21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/sarh.2001.25482","volume":"31","author":"RW McMurray","year":"2001","unstructured":"McMurray RW (2001) Bromocriptine in rheumatic and autoimmune diseases. Semin Arthritis Rheum 31:21\u201332","journal-title":"Semin Arthritis Rheum"},{"key":"2472_CR22","first-page":"639","volume":"17","author":"N Ben-Jonathan","year":"1996","unstructured":"Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW (1996) Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 17:639\u2013669","journal-title":"Endocr Rev"},{"key":"2472_CR23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11102-005-5082-5","volume":"8","author":"A Bellis De","year":"2005","unstructured":"De Bellis A, Bizzarro A, Pivonello R, Lombardi G, Bellastella A (2005) Prolactin and autoimmunity. Pituitary 8:25\u201330","journal-title":"Pituitary"},{"key":"2472_CR24","first-page":"807","volume":"20","author":"L Moszkorzova","year":"2002","unstructured":"Moszkorzova L, Lacinova Z, Marek J, Musilova L, Dohnalova A, Dostal C (2002) Hyperprolactinemia in patients with systemic lupus erythematosus. Clin Exp Rheumatol 20:807\u2013812","journal-title":"Clin Exp Rheumatol"},{"key":"2472_CR25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/rheumatology\/kei115","volume":"45","author":"A Leanos-Miranda","year":"2006","unstructured":"Leanos-Miranda A, Cardenas-Mondragon G (2006) Serum free prolactin concentrations in patients with systemic lupus erythematosus are associated with lupus activity. Rheumatology 45:97\u2013101","journal-title":"Rheumatology"},{"key":"2472_CR26","first-page":"849","volume":"28","author":"M Fojt\u00edkov\u00e1","year":"2010","unstructured":"Fojt\u00edkov\u00e1 M, Tomasov\u00e1 Stud\u00fdnkov\u00e1 J, Filkov\u00e1 M, Lacinov\u00e1 Z, Gatterov\u00e1 J, Pavelka K, Vencovsk\u00fd J, Senolt L (2010) Elevated prolactin levels in patients with rheumatoid arthritis: association with disease activity and structural damage. Clin Exp Rheumatol 28:849\u2013854","journal-title":"Clin Exp Rheumatol"},{"key":"2472_CR27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2230.2010.03871.x","volume":"36","author":"E Dilme-Carreras","year":"2011","unstructured":"Dilme-Carreras E, Martin-Ezquerra G, Sanchez-Regana M, Umbert-Millet P (2011) Serum prolactin levels in psoriasis and correlation with cutaneous disease activity. Clin Exp Dermatol 36:29\u201332","journal-title":"Clin Exp Dermatol"},{"key":"2472_CR28","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-4632.2010.04752.x","volume":"50","author":"EA El-Khateeb","year":"2011","unstructured":"El-Khateeb EA, Zuel-Fakkar NM, Eid SM, Abdul-Wahab SE (2011) Prolactin level is significantly elevated in lesional skin of patients with psoriasis. Int J Dermatol 50:693\u2013696","journal-title":"Int J Dermatol"},{"key":"2472_CR29","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.clinbiochem.2011.07.009","volume":"44","author":"H Malligarjunan","year":"2011","unstructured":"Malligarjunan H, Gnanaraj P, Subramanian S, Elango T, Dayalan H (2011) Clinical efficacy of propylthiouracil and its influence on prolactin in psoriatic patients. Clin Biochem 44:1209\u20131213","journal-title":"Clin Biochem"},{"key":"2472_CR30","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1210\/me.8.5.635","volume":"8","author":"M Berwaer","year":"1994","unstructured":"Berwaer M, Martial JA, Davis JR (1994) Characterization of an upstream promoter directing extrapituitary expression of the human prolactin gene. Mol Endocrinol 8:635\u2013642","journal-title":"Mol Endocrinol"},{"key":"2472_CR31","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1677\/jme.0.0220285","volume":"22","author":"GH Reem","year":"1999","unstructured":"Reem GH, Ray DW, Davis JRE (1999) The human prolactin gene upstream promoter is regulated in lymphoid cells by activators of T-cells and by cAMP. J Mol Endocrinol 22:285\u2013292","journal-title":"J Mol Endocrinol"},{"key":"2472_CR32","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/1529-0131(200110)44:10<2358::AID-ART399>3.0.CO;2-K","volume":"44","author":"A Stevens","year":"2001","unstructured":"Stevens A, Ray D, Alansari A, Hajeer A, Thomson W, Donn R, Ollier WE, Worthington J, Davis JR (2001) Characterization of a prolactin gene polymorphism and its associations with systemic lupus erythematosus. Arthritis Rheum 44:2358\u20132366","journal-title":"Arthritis Rheum"},{"key":"2472_CR33","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1191\/096120301717164903","volume":"10","author":"A Stevens","year":"2001","unstructured":"Stevens A, Ray DW, Worthington J, Davis JR (2001) Polymorphisms of the human prolactin gene\u2014implications for production of lymphocyte prolactin and systemic lupus erythematosus. Lupus 10:676\u2013683","journal-title":"Lupus"},{"key":"2472_CR34","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1002\/art.24468","volume":"60","author":"YC Lee","year":"2009","unstructured":"Lee YC, Raychaudhuri S, Cui J, De Vivo I, Ding B, Alfredsson L, Padyukov L, Costenbader KH, Seielstad M, Graham RR, Klareskog L, Gregersen PK, Plenge RM, Karlson EW (2009) The PRL -1149 G\/T polymorphism and rheumatoid arthritis susceptibility. Arthritis Rheum 60:1250\u20131254","journal-title":"Arthritis Rheum"},{"key":"2472_CR35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","volume":"3","author":"JM Moll","year":"1973","unstructured":"Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55\u201378","journal-title":"Semin Arthritis Rheum"},{"key":"2472_CR36","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/1523-1747.ep12319304","volume":"109","author":"E Mallon","year":"1997","unstructured":"Mallon E, Bunce M, Wojnarowska F, Welsh K (1997) HLA-Cw*0602 is a susceptibility factor in type I psoriasis, and evidence Ala-73 is increased in male type I psoriatics. J Invest Dermatol 109:183\u2013186","journal-title":"J Invest Dermatol"},{"key":"2472_CR37","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/sj.jid.5700118","volume":"126","author":"JE Gudjonsson","year":"2006","unstructured":"Gudjonsson JE, Karason A, Runarsdottir EH, Antonsdottir AA, Hauksson VB, J\u00f3nsson HH, Gulcher J, Stefansson K, Valdimarsson H (2006) Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients\u2013an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol 126:740\u2013745","journal-title":"J Invest Dermatol"},{"key":"2472_CR38","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1744-313X.2005.00543.x","volume":"32","author":"A Sczcerkowska Dobosz","year":"2005","unstructured":"Sczcerkowska Dobosz A, Rebala K, Szczerkowska Z, Nedoszytko B (2005) HLA-C locus alleles distribution in patients from northern Poland with psoriatic arthritis: preliminary report. Int J Immunogenet 32:389\u2013391","journal-title":"Int J Immunogenet"},{"key":"2472_CR39","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0198-8859(98)00123-2","volume":"60","author":"DD Gladman","year":"1999","unstructured":"Gladman DD, Cheung C, Ng CM, Wade JA (1999) HLA-C locus alleles in patients with psoriatic arthritis (PsA). Hum Immunol 60:259\u2013261","journal-title":"Hum Immunol"},{"key":"2472_CR40","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/ard.2007.071399","volume":"67","author":"PY Ho","year":"2008","unstructured":"Ho PY, Barton A, Worthington J, Plant D, Griffiths CE, Young HS, Bradburn P, Thomson W, Silman AJ, Bruce IN (2008) Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriasis arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Ann Rheum Dis 67:677\u2013682","journal-title":"Ann Rheum Dis"},{"key":"2472_CR41","first-page":"505","volume":"30","author":"R Queiro","year":"2003","unstructured":"Queiro R, Torre JC, Gonz\u00e1lez S, L\u00f3pez-Larrea C, Tintur\u00e9 T, L\u00f3pez-Lagunas I (2003) HLA antigens may influence the age of onset of psoriasis and psoriatic arthritis. J Rheumatol 30:505\u2013507","journal-title":"J Rheumatol"},{"key":"2472_CR42","doi-asserted-by":"crossref","first-page":"R185","DOI":"10.1186\/ar2097","volume":"8","author":"R Queiro","year":"2006","unstructured":"Queiro R, Gonzales S, Lopez-Larrea C, Alperi M, Sarasqueta C, Riestra JL, Ballina J (2006) HLA-C locus alleles may modulate the clinical expression of psoriatic arthritis. Arthritis Res Ther 8:R185","journal-title":"Arthritis Res Ther"},{"key":"2472_CR43","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1210\/me.8.3.356","volume":"8","author":"B Gellersen","year":"1994","unstructured":"Gellersen B, Kempf R, Telgmann R, DiMattia GE (1994) Nonpituitary human prolactin gene transcription is independent of Pit-1 and differentially controlled in lymphocytes and in endometrial stroma. Mol Endocrinol 8:356\u2013357","journal-title":"Mol Endocrinol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-012-2472-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-012-2472-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-012-2472-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T05:41:46Z","timestamp":1743831706000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-012-2472-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,22]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["2472"],"URL":"https:\/\/doi.org\/10.1007\/s00296-012-2472-7","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"type":"print","value":"0172-8172"},{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2012,7,22]]}}}